Indeed, AICD expressing transgenic mice recapitulate such AD pathologies as activation of glycogen synthase kinase-3β (GSK3β), phosphorylation and aggregation of Tau, deficits in working memory and abnormal neural activity and silent seizures [23]–[25]. The gene discussed is MAPT; the disease is Alzheimer disease.